Abatacept Treatment in Polymyositis and Dermatomyositis - Artemis UK

Karolinska University Hospital0 个研究点目标入组 20 人开始时间: 2012年4月20日最近更新: 2014年5月12日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 20

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Patients with definite or probable polymyositis or dermatomyositis dignosed according to the diagnostic criteria by Bohan and Peter (30,31).
•2. For patients with polymyositis, a muscle biopsy is required (performed at any time before the start of the study) to confirm the disease and to exclude other conditions (unless a patient is positive for myositis specific or associated autoantibodies).
•3. Polymyositis patients will be included only after agreement by the three Principal Investigators.
•4. Inflammatory active disease based on persisting or worsening muscle weakness, MMT = 150 or low endurance, FI-2 = 20% of upper value together with at least one other sign of active disease: elevated serum levels of muscle enzymes (CK, LD, ASAT, ALAT, above upper limit and being explained by muscle involvement and not eg. liver disease), inflammation in recent muscle biopsy (=3 months) or on MRI scans or active extramuscular disease: skin rash, arthritis or interstitial; lung disease (ILD) (as suggested by chest X-ray, high resolution computerised tomography (HRCT), or pulmonary function test).
•5. Persisting disease activity after a minimum of 3 months treatment with prednisolone or equal drug. The treatment with prednisolone (or equal) should include the dose of at least 0.75 mg/kg/day for at least 1 month in the history and should be stable 1 month prior the baseline visit. Maximum dose of glucocorticoids should not exceed the equivalent of Prednisone 30 mg per day at the time of randomisation.
•6. Combination with at least one other immunosuppressive drug, which includes methotrexate (minimum dose 15 mg/week) or azathioprine (minimum dose 100 mg/day) for at least 3 months. The dose of methotrexate or azathioprine should be stable for at least 1 month before the first administration of abatacept.
•7. If methotrexate or azathioprine has had to be stopped or the dose decreased due to documented intolerance, lower dose or absence of these drugs is accepted provided this situation is stable for 1 month before the baseline.
•8. Age between 18 - 80 years.
•9. Signed informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 6
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 6

排除标准

•1. Patients with other types of inflammatory myopathies including:
•- Drug induced myositis.
•- Inclusion body myositis
•- Malignancy associated myositis
•2. Women who are pregnant or breastfeeding.
•3. Women with a positive pregnancy test on enrolment or prior to start of study drug administration.
•4. Women of child bearing age who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for 10 weeks after the last infusion of study medication.
•5. Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological, ophthalmologic or cerebral disease with the exception of those symptoms that are a manifestation of polymyositis or dermatomyositis. Concomitant medical conditions that in the opinion of the investigator might place the subject at unacceptable risk for participation in this study.
•6. Subjects with a history of cancer within the last five years (other than non-melanoma skin cell cancers cured by local resection). Existing non-melanoma skin cell cancers must be removed prior to dosing. Patients with dermatomyositis need to be screened for malignancies according to routine procedures.
•7. Subjects who have a history of clinically significant drug or alcohol abuse. Subjects currently taking methotrexate who admit to consumption of more than an average of 1 alcoholic drink per day.
•8. Subjects with any serious bacterial infection (such as pneumonia, other renal infection and sinusitis), unless treated and resolved with antibiotics or chronic bacterial infection (such as pyelonephritis and chest infection with bronchiectasis) in the previous 3 months.
•9. Subjects with active tuberculosis requiring treatment within the previous 3 years. Subjects with a positive PPD at screening will not be eligible for the study unless they completed treatment for latent TB and have a negative chest x-ray at enrolment. A PPD response that is equal to or greater than 10 mm should be considered a positive test, although more conservative criteria may be applied as determined by the clinical circumstance and investigator according to published guidelines and/or local standards endorsed by the medical society. Quantiferon assay may replace PPD testing and patients are excluded from the study if the test is positive. Quantiferon positive patients who completed treatment for latent tuberculosis according to the local guidelines may be considered for enrolment.
•10. Subjects with herpes zoster that resolved less than 2 months prior to enrolment.
•11. Subjects with evidence (as assessed by the Investigator) of active or latent bacterial or viral infections at the time of potential enrolment, including subjects with evidence of Human Immunodeficiency Virus (HIV) infection.
•12. Significant toxicities associated with concomitant or previous immunosuppressive
•therapy and anti-TNF therapy that would preclude subjects from participating and completing the study.
•13. Patients with clinically apparent immunodeficiency syndrome, (IgA deficiency alone is not an exclusion criterion)
•14. Subjects with any of the following laboratory values:
•Hgb < 8.5 g/dL.
•WBC < 3,000/mm3 (3 x 109/L).
•Platelets < 100,000/mm3 (100 x 109/L).
•Serum creatinine > 2 times upper limit of normal.
•Any other laboratory test results that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study.
•15. Subjects previously tr

研究者

发起方

Karolinska University Hospital

相似试验

进行中（未招募）

1 期

Abatacept treatment in polymyositis and dermatomyositis - ARTEMISpolymyositis and dermatomyositisMedDRA version: 12.1Level: LLTClassification code 10036102Term: PolymyositisMedDRA version: 12.1Level: LLTClassification code 10012503Term: Dermatomyositis

EUCTR2009-015957-20-CZKarolinska University Hospital20

进行中（未招募）

不适用

EUCTR2009-015957-20-SEKarolinska University Hospital20

已完成

2 期

Abatacept Treatment in Polymyositis and DermatomyositisPolymyositisDermatomyositis

NCT01315938Karolinska Institutet20

已完成

不适用

Dexa-Myositis Trial: treatment of polymyositis and dermatomyositis - dexamethasone versus prednisoneMyositis, dermatomyositis, polymyositisMusculoskeletal DiseasesMyositis

ISRCTN48188950Academic Medical Centre (AMC) (Netherlands)80